Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01450761 · ClinicalTrials.gov registry record · Phase 3

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

A Phase 3 study of Small Cell Lung Carcinoma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 3
Development phase
1,351
Enrollment target
20
Study locations

NCT01450761 is a Phase 3 study of Small Cell Lung Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,351 participants, above the 186-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (626% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01450761, a Phase 3 study of Small Cell Lung Carcinoma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 3
Development phase
1,351 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.

Conditions Studied

Small Cell Lung Carcinoma

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Etoposide
  • BIOLOGICAL Ipilimumab
  • BIOLOGICAL Placebo matching Ipilimumab

Study Locations (20)

Florida

  • Florida Cancer Specialists S. - Fort Myers
  • Cancer Specialists, LLC - Jacksonville
  • Lake City Cancer Care - Lake City
  • Florida Cancer Specialists - St. Petersburg

Illinois

  • Quincy Medical Group - Quincy
  • Presence Medical Group Hematology Oncology - Skokie
  • SIU School Of Medicine - Springfield

Kentucky

  • Ashland Bellefonte Cancer Center - Ashland
  • University Of Kentucky - Lexington
  • Montgomery Cancer Center - Mount Sterling

California

  • Sutter Medical Center - Auburn
  • UCSD Moores Cancer Center - La Jolla

Arkansas

  • Genesis Cancer Center - Hot Springs

Colorado

  • University Of Colorado Cancer Center - Aurora

Georgia

  • Medical Oncology, LLC - Augusta

Indiana

  • St. Francis Medical Group Oncology And Hematology Specialist - Indianapolis

Trial Details

FieldValue
Enrollment Target 1,351 participants
Start Date 2011-12-13
Est. Completion 2017-05-17
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01450761

The ClinicalTrials.gov registry entry for NCT01450761 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,351 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (626% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT01450761 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, Kentucky.

Frequently Asked Questions

What is clinical trial NCT01450761 about?

NCT01450761 is a clinical study titled "Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone". The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.

What is the current status of trial NCT01450761?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,351 participants. The study started on 2011-12-13. Estimated completion is 2017-05-17.

What conditions does trial NCT01450761 study?

This clinical trial studies the following conditions: Small Cell Lung Carcinoma.

What interventions are being tested in trial NCT01450761?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Ipilimumab (BIOLOGICAL), Placebo matching Ipilimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT01450761?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01450761 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small Cell Lung Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small Cell Lung Carcinoma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.